EUDA Health Holdings announces the launch of Regenixé Mask, expanding its Helixé product line with advanced skincare technology.
Quiver AI Summary
EUDA Health Holdings Limited, a Singapore-based non-invasive healthcare provider, has announced the expansion of its Helixé product line with the launch of the Regenixé iPSC-derived Skin Stem Cell Secretome Mask, developed by Chemokine Pte Ltd. EUDA has exclusive global distributorship rights for Helixé products, which also include a next-generation immune health supplement. The Regenixé Mask is designed to enhance skin hydration and recovery using advanced secretome technology. The global face mask market is projected to grow significantly, particularly in the Asia-Pacific region, where EUDA intends to leverage its distribution networks to drive sales of the new product. The company aims to address the healthcare needs in Asia, where a rapidly aging population presents increasing demand for innovative health solutions.
Potential Positives
- EUDA is expanding its product line with the launch of the Regenixé iPSC-derived Skin Stem Cell Secretome Mask, enhancing its presence in the beauty and wellness market.
- The company holds exclusive global distributorship rights for Helixé products, positioning it well for significant sales growth.
- The global face mask market is projected to grow substantially, providing EUDA with an opportunity to capitalize on this expanding market segment.
- EUDA plans to leverage its existing distribution networks and partnerships in the Asia-Pacific region, potentially driving strong sales for the Regenixé Mask and other Helixé products.
Potential Negatives
- The press release emphasizes the uncertainty associated with the company's forward-looking statements, highlighting potential risks and the possibility that actual results may differ significantly from expectations.
- The reliance on subjective judgment and assumptions for estimates and projections may lead to concerns regarding the accuracy of the company's future plans and financial performance.
- The disclaimer regarding no obligation to update forward-looking statements could raise apprehensions among investors about the company's commitment to transparency and accountability.
FAQ
What is the Regenixé Mask?
The Regenixé Mask is a skincare product made from iPSC-derived skin stem cell secretome technology aimed at enhancing skin hydration and recovery.
Who developed the Regenixé Mask?
The Regenixé Mask was developed by Chemokine Pte Ltd, a biotech company focused on molecular supplements and gene-modulating formulations.
What markets is EUDA targeting with the Regenixé Mask?
EUDA is targeting the Asia-Pacific region, particularly Singapore, Malaysia, and China, for the distribution of the Regenixé Mask.
What are the expected industry trends for face masks?
The global face mask market is projected to grow from approximately US$7.95 billion in 2026 to US$9.08 billion by 2031 due to rising consumer demand.
What is EUDA's strategic focus?
EUDA aims to lead in non-invasive healthcare, specifically within the longevity sector, catering to the rapidly aging population in Asia.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$EUDA Hedge Fund Activity
We have seen 0 institutional investors add shares of $EUDA stock to their portfolio, and 5 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CITADEL ADVISORS LLC removed 2,232 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $5,155
- JANE STREET GROUP, LLC removed 1,284 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $12,718
- GEODE CAPITAL MANAGEMENT, LLC removed 1,033 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $10,231
- UBS GROUP AG removed 36 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $356
- SBI SECURITIES CO., LTD. removed 1 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $9
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Full Release
SINGAPORE, June 01, 2026 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ: EUDA) (“EUDA” or the “Company”), a Singapore-based non-invasive healthcare provider in Asia with a focus on Singapore, Malaysia and China, today announced it is expanding the Helixé product line with the launch of the Regenixé iPSC-derived Skin Stem Cell Secretome Mask (“Regenixé Mask”), a beauty product developed by Chemokine Pte Ltd (“Chemokine”).
EUDA holds the exclusive global distributorship rights for Helixé products, that includes but is not limited to, a next-generation immune health supplement, from Chemokine, a Singapore-based biotech company focused on molecular supplements and gene-modulating formulations.
Regenixé Mask is formulated with iPSC-derived skin stem cell secretome technology and cellulose mask technology designed to support skin hydration, brightening, and overall recovery. EUDA believes secretome-based skincare products represent a growing category within the premium beauty and wellness market. According to Mordor Intelligence’s Face Mask Market Report, the global face mask market is estimated to be approximately US$7.95 billion in 2026 and is forecast to reach approximately US$9.08 billion by 2031, driven by growing consumer demand for skincare, beauty, and wellness products. Asia-Pacific remains one of the largest regions for facial masks and skincare products, led by demand from China, South Korea, Japan, and Southeast Asia.
EUDA intends to leverage its established distribution networks and regional wellness partnerships in Malaysia and China to drive sales and distribution of the Regenixé Mask and expand the broader Helixé product line across the Asia-Pacific region.
About EUDA Health Holdings Limited
EUDA Health Holdings Limited (NASDAQ: EUDA) is a Singapore-based non-invasive healthcare provider in Asia with a focus on Singapore, Malaysia and China. The Company aims to become a market leader in non-invasive and preventive healthcare, with a strategic focus on the fast-growing longevity sector. Our mission is to address the evolving healthcare needs of over approximately 1.8 billion people across the region which are experiencing significant demographic shifts as more than approximately 30% of the population ages rapidly. EUDA believes that by offering innovative, accessible, and science-backed health solutions, it is positioned to lead the transformation of regional healthcare from reactive medical treatment to proactive, longevity-focused care. EUDA also runs a Singapore-based property management business.
Forward-Looking Statements
Certain statements in this press release that are not historical facts constitute “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Any statements that refer to expectations or other characterizations of future events, circumstances or results are forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. The factors may include, but not be limited to, factors related to the Company’s anticipated growth strategies, future business development, ability to develop new products, expand to other related industries or markets, and other information detailed from time to time in the filings and future filings with the United States Securities and Exchange Commission. The views expressed are those of management and are based on currently available information. Estimates and projections contained herein have been prepared by management and involve significant elements of subjective judgment and analysis and are based on certain assumptions. No representation nor warranty, expressed or implied, is made as to the accuracy or completeness of the information contained in this document, and nothing contained herein is, or shall be relied upon, as a promise or representation, whether as to the past or the future. You are cautioned not to place undue reliance on these forward-looking statements.
This press release is intended solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy the Company’s stock. This press release is based upon information available to the public, as well as other information from sources which management believes to be reliable, but is not guaranteed by the Company as being accurate nor does it purport to be complete. Opinions expressed herein are those of management as of the date of publication and are subject to change without notice. Except for ongoing obligations of the Company to disclose material information under the federal securities laws, the Company does not undertake any obligation to release any revisions to any forward-looking statements, to report events or to report the occurrence of unanticipated events.
Christensen Advisory
Christian Arnell
Phone: + 852 9040 0621
Email:
[email protected]